Association between chronic hepatitis B infection and metabolic syndrome

Zhao, Xiaohui; Shah, Drishti; Sambamoorthi, Usha

doi:10.1007/s40200-018-0364-4

Cited by 8 publications

(5 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…32 On the other hand, in a cross-sectional study of almost 35,000 adults, an inverse association between CHB and metabolic syndrome was noted, although the underlying mechanism was unclear. 33 Our study found a significantly higher prevalence of metabolic risk factors among NAFLD patients and CHB patients with hepatic steatosis, compared to CHB patients without hepatic steatosis. A Hong Kong based large prospective cohort study has shown an increased risk of cardiovascular events among CHB patients suffering from metabolic risk factors while higher incidents of HCC in CHB patients with metabolic risk factors were seen in a study from Taiwan.…”

Section: Discussionsupporting

confidence: 44%

“…Multiple studies have described a strong bidirectional relationship between NAFLD and metabolic risk factors, and hence the high prevalence of metabolic risk factors among NAFLD patients 32 . On the other hand, in a cross‐sectional study of almost 35,000 adults, an inverse association between CHB and metabolic syndrome was noted, although the underlying mechanism was unclear 33 . Our study found a significantly higher prevalence of metabolic risk factors among NAFLD patients and CHB patients with hepatic steatosis, compared to CHB patients without hepatic steatosis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B: The multicentre, prospective CAP‐Asia study

Leow

Chan

Goh

et al. 2023

Journal of Viral Hepatitis

View full text Add to dashboard Cite

We aimed to compare the severity of liver disease, metabolic profile and cardiovascular disease (CVD) risk of chronic hepatitis B (CHB) patients with and without hepatic steatosis and patients with non-alcoholic fatty liver disease (NAFLD). Patients with NAFLD and CHB were prospectively enrolled from 10 Asian centres. Fibroscan was performed for all patients and hepatic steatosis was defined based on controlled attenuation parameter >248 dB/m. CVD risk was assessed using the Framingham risk score. The data for 1080 patients were analysed (67% NAFLD, 33% CHB). A high proportion (59%) of CHB patients had hepatic steatosis. There was a significant stepwise increase in alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transpeptidase, controlled attenuation parameter and liver stiffness measurement, from CHB patients without hepatic steatosis to CHB patients with hepatic steatosis to NAFLD patients (p < 0.001 for all comparisons). There was a significant stepwise increase in the proportion of patients with metabolic syndrome and in CVD risk, with very high or extreme CVD risk seen in 20%, 48% and 61%, across the groups (p < 0.001 between CHB patients with and without hepatic steatosis and p < 0.05 between CHB patients with hepatic steatosis and NAFLD patients). In conclusion,

show abstract

Section: Discussionsupporting

confidence: 44%

Section: Discussionmentioning

confidence: 99%

Hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B: The multicentre, prospective CAP‐Asia study

Leow

Chan

Goh

et al. 2023

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

“…Our study group included only adults and as such, the prevalence of HBV infection among our study group was slightly higher than the prevalence for the general population. The relationship between HBV and MetS remains inconclusive [10][11][12][13][14][15][16][17][18] , with some studies reporting a protective effect of HBsAg seropositivity against MetS while other studies found no association between HBsAg positivity and MetS 20 . It is important to note, however, that most studies regarding the association between HBV and MetS have been performed in Taiwan, Japan, Korea, Slovakia and the United States, with few studies having been conducted in China.…”

Section: Discussionmentioning

confidence: 99%

Association between Hepatitis B Virus Infection and Metabolic Syndrome in Southwest China: A Cross-sectional Study

Yan

Liao

Han

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Hong tang 1 ✉ the correlation between hepatitis B virus (HBV) infection and metabolic syndrome (MetS) remains to be clarified. In this study, we explored this association in a large population in Southwest China. This was a cross-sectional study, with pooled adult health data. Multivariate logistic regression analysis, controlling for age, sex, HBV status, alanine aminotransferase, and fatty liver, was used to identify predictor(s) of MetS. Of the 96,175 participants, positive HBV was identified in 7984 (8.30%) and MetS in 12,092 (12.57%). The MetS prevalence was lower among HBV positive than negative individuals (11.64% versus 12.66%, P < 0.001). The adjusted odds (aOR) of positive HBV among individuals with MetS was 0.841 (95% confidence interval (CI), 0.771-0.916) in men and 0.834 (95% CI, 0.672-0.925) in women. Elevated triglyceride level, a component of MetS, was inversely associated with HBV status in both men and women: aOR, 0.551 (95% CI, 0.514-0.590) and 0.683 (95% CI, 0.605-0.769), respectively. Among HBV positive individuals, liver cirrhosis was more common among those with than without MetS (4.83% versus 2.93%, respectively; P = 0.002). HBsAg-seropositive are inversely associated with MetS, especially elevated triglycerides. Liver cirrhosis was more common among HBV infection patients with MetS. Chronic hepatitis B virus (HBV) infection is a major public health issue 1. HBV infection is not only the cause of acute and chronic hepatitis, but is also one of the key etiological factors of liver cirrhosis and hepatocellular carcinoma (HCC). In 2015, it was estimated that 257 million people, 3.5% of the world's population, were living with a chronic HBV infection 2. In China, a HBV-endemic region, the prevalence of HBV infection for population among individual 1 to 59 years of age is approximately 7.18%, with an estimated 93 million patients individuals in China living with a chronic HBV infection 3. Although the health morbidities of chronic HBV infection are decreasing, these remain a tremendous healthcare burden in China. Considering that the liver plays a key role in glucose homeostasis and lipid metabolism, the possible association between liver disease and diabetes mellitus or metabolic syndrome (MetS) has been a topic of healthcare research interest. MetS refers to diseases caused by metabolic disturbances, such as increased waist circumference, hyperglycemia, elevated blood pressure (BP), and dyslipidemia. MetS affects approximately one-fifth in China, reflecting the increasing prevalence of obesity 4,5. MetS is characterized by dyslipidemia and glucose metabolism disorders, both of which are influenced by hepatic function. In fact, an association between MetS and non-alcoholic fatty liver disease (NAFLD), chronic hepatitis C (CHC) and HCC has previously been demonstrated 6,7. Additionally, NAFLD is considered as the hepatic manifestation of MetS 8. It is also now widely confirmed that chronic hepatitis C virus infection may increase the risk of insulin resistance and type 2 diabetes 9. MetS is als...

show abstract

“…The natural course of HBV infection may play a role in changes in lipid metabolism, especially in elderly patients[ 36 ]. This inverse relationship between HBV infection and serum lipid profile may also contribute to reducing the prevalence of metabolic syndrome[ 37 , 38 ].…”

Section: Epidemiology Of Steatosis In Chbmentioning

confidence: 99%

Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion

Shi¹,

Yang²,

Fan³

2021

WJG

View full text Add to dashboard Cite

With the increasing incidence of obesity and metabolic syndrome worldwide, concomitant nonalcoholic fatty liver disease (NAFLD) in patients with chronic hepatitis B (CHB) has become highly prevalent. The risk of dual etiologies, outcome, and mechanism of CHB with concomitant NAFLD have not been fully characterized. In this review, we assessed the overlapping prevalence of metabolic disorders and CHB, assessed the risk of advanced fibrosis/hepatocellular carcinoma in CHB patients concomitant with NAFLD, and discussed the remaining clinical issues to be addressed in the outcome of such patients. We also explored the possible roles of hepatitis B virus in the development of steatosis and discussed difficultiesof histological evaluation. For CHB patients, it is important to address concomitant NAFLD through lifestyle management and disease screening to achieve better prognoses. The assessment of progressive changes and novel therapies for CHB patients concomitant with NAFLD deserve further research.

show abstract

Association between chronic hepatitis B infection and metabolic syndrome

Cited by 8 publications

References 48 publications

Hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B: The multicentre, prospective CAP‐Asia study

Hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B: The multicentre, prospective CAP‐Asia study

Association between Hepatitis B Virus Infection and Metabolic Syndrome in Southwest China: A Cross-sectional Study

Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion

Contact Info

Product

Resources

About